Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 19/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 18/20 | 1.00 |
| ▸ | MTOR | P42345 | 8/20 | 0.78 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.59 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.59 |
| ▸ | ATM | Q13315 | 2/20 | 0.59 |
| ▸ | CSF1R | P07333 | 1/20 | 0.59 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.59 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29492845 | 1.00 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3CDPIK3CB | |
| SCHEMBL24270869 | 0.88 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3CDPIK3CB | |
| SCHEMBL29492733 | 0.88 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3CDPIK3CB | |
| SCHEMBL29492843 | 0.88 | PIK3CA (0.78) | PRKDCPIK3CAMTORPIK3CDPIK3CB | |
| SCHEMBL24270530 | 0.88 | PIK3CA (0.78) | PRKDCPIK3CAMTORPIK3CDPIK3CB | |
| SCHEMBL24270482 | 0.85 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3CDPIK3CB | |
| SCHEMBL29492675 | 0.85 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3CDPIK3CB | |
| SCHEMBL29492798 | 0.84 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3CDPIK3CB | |
| SCHEMBL24270652 | 0.84 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3CDPIK3CB | |
| SCHEMBL24270622 | 0.81 | PRKDC (0.89) | PRKDCPIK3CAMTORPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365559-A1 | NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER | AUCKLAND UNISERVICES LIMITED (NZ) | 2023-11-16 | — | — | US | disclosed |
| WO-2022064430-A1 | NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER | AUCKLAND UNISERVICES LIMITED (NZ) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365559-A1 | NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER | DCK, DTYMK, TYMP | PRKDC 64/4885PIK3CA 302/4885MTOR 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.